[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropathy-small-fiber\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropathy-small-fiber":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100647160","phase-4-effect-of-tirzepatide-on-diabetic-peripheral-sensorimotor-neuropathy-100647160",false,"NCT07706088","Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy","Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy: A Randomized, Open Label, Controlled Study","T-DPN","Inclusion Criteria:\n\nEligible participants (≥ 18 years) with diabetes duration of \\\u003C 10 years, baseline HbA1c between 7% and 10% Signs and symptoms of DSPN based on a Michigan Neuropathy Screening Instrument (MNSI) history composite score of \\>= 7 OR MNSI examination SCORE \\>= 2.5 will be enrolled.\n\nBMI \\>= 27 KG\u002Fmetre 2.\n\nExclusion Criteria:\n\n1. participants with untreated hypothyroidism\n2. history of leprosy\n3. peripheral vascular disease defined by ankle-brachial index (ABI) \\< 0.9\n4. serum B12 levels \\\u003C 200 pg.\u002FmL\u002F if low will be supplemented\n5. history of alcohol excess (\\>=2 and \\>= 1 standard drink per day for male and female respectively)\n6. any condition affecting corneal nerves (severe dry eyes, severe corneal dystrophies, ocular trauma or surgery in the preceding 6 months or Sjogren\\'s or sicca syndrome\n7. use of oral contraceptives.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration.\n\nUsing tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM \u002F NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.",[27,28],"Neuropathy, Small Fiber","Diabete Mellitus",[30,31,32],"diabetes","neuropathy","tirzepatide","NOT_YET_RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-15","ACTUAL",{"date":39,"type":21},"2026-07",{"date":41,"type":21},"2028-07-01",{"name":43,"class":44},"Post Graduate Institute of Medical Education and Research, Chandigarh","OTHER"]